Treating TRK fusion cancer: Selecting between available agents
Treating TRK fusion cancer: Selecting between available agents
CARTs for the treatment of T-cell malignancies
Testing and treatment for CDH1 in hereditary diffuse gastric cancer and breast cancer
Haematological malignancies: Latest advances from ASH 2019
Updates in treating NTRK fusion cancer: Highlights from ESMO 2019
Management of mutation-negative NSCLC
Management of advanced cervical cancer
Systematic therapy of driver mutated NSCLC
KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC
Integrative molecular characterisation of S/R RCC to reveal determinants of poor prognosis and response to ICIs
Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy
NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer